Rocket Pharma Reports Q4 2023 Net Loss of $59.7M; PDUFA Date for KRESLADI Set for June 30, 2024

ROCKET PHARMACEUTICALS, INC.

2023-FY EPS reported -$2.92

Cash, cash equivalents and investments stood at $407.5M as of Dec 31, 2023, providing runway into 2026.
Net loss for Q4 2023 was $59.7M ($0.64 per share); full year 2023 net loss $245.6M ($2.92 per share).
FDA extended Priority Review of KRESLADI BLA for severe LAD-I to June 30, 2024; no advisory committee needed.
Fanconi Anemia BLA and MAA filings remain on track for H1 2024; pipeline milestones for 2024 reaffirmed.
Appointed R. Keith Woods to Board; he previously led commercialization of Vyvgart at argenx.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ROCKET PHARMACEUTICALS, INC. reported the fourth quarter and year ended December 31, 2023 results: net income Net loss was $59.7 million and $245.6 million or $0.64 and $2.92 per share (basic and diluted) for the three and twelve, EPS $0.64 and $2.92 per share (basic and diluted) for the three and twelve months ended December 31, 2023.

Period: the fourth quarter and year ended December 31, 2023
Net income: Net loss was $59.7 million and $245.6 million or $0.64 and $2.92 per share (basic and diluted) for the three and twelve
EPS: $0.64 and $2.92 per share (basic and diluted) for the three and twelve months ended December 31, 2023
Result: reported results

Exact text from the filing

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress

View on SEC.gov

Browse all earnings releases →

ROCKET PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001140361-24-009506

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.